CG Labz
Peptide Library / Recovery / Neuro

ARA-290 (Cibinetide)

EPO-derived (Helix B) peptide

ARA-290 (Cibinetide) Research Protocol

Complete Research Guide 4 min read1 peer-reviewed references

Quickstart Overview

ARA-290 is an 11-amino-acid peptide derived from the Helix B region of erythropoietin (EPO). It activates the tissue-protective 'innate repair receptor' without EPO's effect on red-blood-cell production, and is studied for neuropathic pain and tissue protection.

Reconstitution
Add 2.0 mL bacteriostatic water to a 10 mg vial → 5 mg/mL
Literature Range
2–4 mg per administration
Measuring Reference
At 5 mg/mL: 2 mg = 0.4 mL = 40 units
Frequency
Once daily
Route (studies)
Subcutaneous
Cycle
4 weeks

Scientific Data

Molecular Formula
—
Molecular Weight
1259.4 Da
Sequence
QEQLERALNSS
Sequence Length
11
CAS
Research compound
Peptide Family
Innate-repair peptide
Half-life
Refer to published literature
Solubility
Bacteriostatic water, sterile saline
Storage
Lyophilized: -20°C. Reconstituted: 2–8°C, use within 2–4 weeks.
Appearance
White lyophilized powder
Standard: 10 mg vial · 2 mL diluent

Dosing & Reconstitution Guide

Interactive Reconstitution
Adjust vial size, diluent and target dose. Results update live.
Full Precision Calculator →
Concentration
5.00 mg/mL
Draw Volume
0.400 mL
Syringe Units
40.0 U
Doses / Vial
5

Units assume a U-100 insulin syringe (100 units = 1 mL). Tissue-protective EPO-derived peptide with no red-cell-stimulating activity.

Frequency: Once daily

Reconstitution Steps

  1. 1Allow the lyophilized vial and bacteriostatic water to reach room temperature (~15 min).
  2. 2Swab both vial stoppers with a fresh 70% isopropyl alcohol pad and let them dry.
  3. 3Draw 2.0 mL of bacteriostatic water into a mixing syringe.
  4. 4Insert at an angle and let the water run slowly down the glass wall — never directly onto the powder.
  5. 5Gently swirl (do not shake) until the solution is completely clear.
  6. 6Label with date and concentration (mg/mL) and refrigerate at 2–8 °C immediately.

Supplies Needed

Planning example for a 4-week protocol at approximately 2000 mcg per day.

Peptide (10 mg vials)
Estimate vials from total mass: 2000 mcg/day × 28 days.
Bacteriostatic Water
One 10–30 mL vial typically covers a full cycle.
Insulin Syringes (U-100)
One per administration (29–31 G, 0.3–0.5 mL).
Alcohol Swabs
Two per administration (vial + site).
Sharps Container
Required for safe disposal.

Protocol Overview

Goal
Model innate-repair-receptor tissue protection and nerve repair.
Schedule
Daily, ~4 weeks.
Dose Range
2–4 mg/day.

Dosing Protocol

Standard
2–4 mg once daily
Frequency
Once daily
Target
4 mg/day studied
Cycle Length
4 weeks typical in trials
Timing
Not time-critical
Route
Subcutaneous

Storage Instructions

Lyophilized
−20 °C long term (18–24 months); stable at room temperature for short transit.
Reconstituted
2–8 °C refrigerated; use within 4 weeks.
Light
Protect from direct light; keep in the original carton.
Freeze/Thaw
Avoid repeat freeze–thaw cycles after reconstitution.

Important Notes

  • Well tolerated in trials; no erythropoietic effect.
  • Studied mainly for small-fibre neuropathy and sarcoidosis.

How This Works

ARA-290 binds the innate repair receptor (a heteromer of the EPO receptor and the β-common receptor) expressed on injured and inflamed tissue. Activation triggers anti-inflammatory, anti-apoptotic and tissue-protective signalling and promotes small-nerve-fibre repair — relevant to neuropathic pain in sarcoidosis and diabetes — all without stimulating erythropoiesis, avoiding EPO's thrombotic risks.

Potential Benefits & Side Effects

Reported in research
  • Tissue-protective, anti-inflammatory signalling
  • Small-nerve-fibre repair and reduced neuropathic pain
  • No erythropoietic (red-cell) effect — avoids EPO's risks
  • Improved quality-of-life metrics in sarcoidosis neuropathy studies
Possible considerations
  • Injection-site reactions
  • Generally well tolerated in trials
  • Limited long-term data
  • Mild transient effects reported

Lifestyle Factors

  • Adequate hydration and 7–9 h of sleep are standard controls in most research protocols.
  • Consistent dose timing improves the reliability of any self-tracked endpoints.
  • Maintain a clean, sterile workflow for every draw to avoid contamination.

Injection Technique

  1. 1Wash hands, then prep the vial top and the target site with separate alcohol swabs.
  2. 2Pinch a subcutaneous skin fold (abdomen, ~2 inches from the navel) and insert at 45–90°.
  3. 3Depress the plunger slowly over 3–5 seconds, hold 5 seconds, then withdraw.
  4. 4Rotate sites each administration and dispose of the syringe in a sharps container.

Frequently Asked Questions

Third-party HPLC testing

CG Labz Verified Batches

No published batches yet.

Research Disclaimer

All compounds are supplied strictly for laboratory research. Dosing figures below summarize ranges reported in published preclinical and clinical literature for reference purposes only. CG Labz does not provide medical advice or individualized dosing recommendations.

Peer-reviewed literature

References

  1. [1] Molecular Medicine
    Brines M. et al. ARA-290, a nonerythropoietic peptide, and tissue protection.
    View Source